title: Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
abstract: Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of rare non-Hodgkin lymphomas that arise in the skin. In advanced stages, CTCL becomes systemic and is associated with poor prognosis. Diagnosis of CTCL and treatment of early-stage disease with topical therapies often occurs under the care of a dermatologist. Community oncologists see few patients with CTCL due to direct referrals from dermatologists to academic or lymphoma specialty centers. However, some patients will continue to be managed in a community setting. Currently there is no evidence-based stepwise algorithm for treatment of patients with CTCL, and guidelines suggest a wide range of systemic therapies, including biologics, targeted agents, and more traditional chemotherapies. To provide optimal care in a community setting, oncologists must become familiar with newer nonchemotherapeutic treatment options. This review highlights romidepsin, a histone deacetylase inhibitor approved for the treatment of patients with CTCL who have received ≥1 prior systemic therapy.
authors.affiliation: Stanford Cancer Center, 875 Blake Wilbur Drive, CC 2232, Stanford, CA 94305, United States. Electronic address: sreddy@stanford.edu.
authors.forename: Sunil A
authors.initials: SA
authors.lastname: Reddy
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D047630:Depsipeptides / Q000008:administration & dosage*; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage; D006801:Humans; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; C087123:romidepsin
keywords: Cutaneous T-cell lymphoma; Histone deacetylase inhibitor; Romidepsin